Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Proteomics
Research from University of London, Imperial College has provided new information about proteomics
March 24th, 2009
"Targeting specific receptors is attracting growing interest in the fields of drug delivery and gene therapy for cancer treatment. The urokinase plasminogen activator receptor (uPAR) is overexpressed on many tumors, particularly that of prostate and breast cancers," investigators in London, the United Kingdom report. "The aim of this study is to design, prepare, and characterize a synthetic self-assembled nanoparticle that presents targeting ligands at a certain conformation and molar ratio on the surface of the particles. Here, we describe the synthesis of a novel uPAR targeting ligand consisting of an I I-amino-acid sequence named U11 peptide modified with an alkyl...
Source: Cancer Weekly (2009-03-24)
|
